Rethinking Cardiovascular Risk in Europe.... to stop heart disease from
being a leading cause of death.

Amarin's Innovation in Cardiovascular Disease (CVD) Management

Working together to advance pathways in cardiovascular risk management

Cardiovascular disease management requires commitment and innovation. Despite optimal management of risk factors such as low-density lipoprotein cholesterol (LDL-C), many patients remain at risk of cardiovascular events.1 To reduce the burden of CVD, emerging therapeutic modalities should be explored to address drivers of residual risk.1

To provide effective cardiovascular prevention, it is crucial to share information on the evolving CVD landscape and discuss central questions in CVD management.

How can we fight cardiovascular disease today?

group shaking hands

If you are looking for a new opportunity, why not join us at Amarin ? Together we can achieve great things and improve patient's lives.

Our Product

We've got exciting plans. Explore our latest news and stay up to date with the innovative work we're doing.

CV – Cardiovascular 
CVD – Cardiovascular disease
LDL-C – Low-density lipoprotein cholesterol


  1. Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The Evolving Understanding and Approach to Residual Cardiovascular Risk Management. Front Cardiovasc Med. 2020;7:88.
  2. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016;37:2999-3058.
UK-NP-00260 Apr 2024